Sponsored communities reduce timelines and increase relevance. Digital engagement allows for rapid study launches and ...

While sparking excitement among biopharma companies focused on rare and ultrarare indications, experts say FDA Commissioner ...

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

While the Trump administration has painted the jettisoning of staff and regulations as good for business, there are multiple ...

As the FDA prepares for a busy Oncologic Drugs Advisory Committee meeting next week, an agency insider told BioSpace that ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Roche committed $50 billion in U.S. manufacturing funds, with which it will construct at least four new facilities.

After warnings that the dragged-out process was putting the cell therapy company at risk of bankruptcy, bluebird bio now has ...